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Background: The gastrointestinal system hosts roughly 1,800 distinct phyla and about
40,000 bacterial classes, which are known as microbiota, and which are able to influence
the brain. For instance, microbiota can also influence the immune response through the
activation of the immune system or through the release of mediators that are able to
cross the brain blood barrier or that can interact with other substances that have free
access to the brain, such as tryptophan and kynurenic acid, which is a metabolite of
tryptophan and which has been involved in the pathogenesis of schizophrenia.
Objectives: This paper reviews the possible relationships between microbiome,
schizophrenia and treatment resistance. Given the possibility of a role of immune
activation and alterations, we also describe the relationship between schizophrenia and
immune inflammatory response. Finally, we report on the studies about the use of
probiotic and prebiotics in schizophrenia.
Methods: Cochrane library and PubMed were searched from the year 2000 to 2018
for publications about microbiome, immune-mediated pathology, schizophrenia and
neurodevelopmental disorders. The following search string was used: (microbiome or
immune mediated) AND (schizophrenia OR neurodevelopmental disorder). Associated
publications were hand-searched from the list of references of the identified papers.
A narrative review was also conducted about the use of probiotics and prebiotics in
schizophrenia.
Results: There exists a close relationship between the central nervous system and
the gastrointestinal tract, which makes it likely that there is a relationship between
schizophrenia, including its resistant forms, and microbiota. This paper provides a
summary of the most important studies that we identified on the topic.
Conclusions: Schizophrenia in particular, remain a challenge for researchers and
practitioners and the possibility of a role of the microbiome and of immune-mediated
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pathology should be better explored, not only in animal models but also in clinical trials
of agents that are able to alter gut microbiota and possibly influence the mechanisms
of gastrointestinal inflammation. Microbiome targeted treatments have not been well-
studied yet in patients with mental illness in general, and with schizophrenia in particular.
Nonetheless, the field is well worth of being appropriately investigated.
Keywords: microbiome, schizophrenia, resistant, inflammation, probiotics, gut, immune, interleukin
INTRODUCTION
Human body is colonized by various bacteria and the majority of
them are within intestines, ranging from <105 bacteria per gram
of digesta in the upper parts of the small intestine, to >1,012
bacteria per gram of digesta in the large intestine (15). Indeed,
the gastrointestinal system hosts roughly 1,800 distinct phyla and
about 40,000 bacterial classes, which are known as microbiota
(Sherwin et al., 2016).
Microbiota main component include the following phyla:
Firmicutes, Bacteroidetes, Proteobacteria, Actino-bacteria,
Fusobacteria, and Verrucomicrobia. Those microorganisms
play important role in maintaining homeostasis and their
imbalance may lead to various diseases (Eckburg et al., 2005).
Newer research has made it clear that the maintenance of gut
homeostasis is important for the prevention and treatment of
various neurological diseases, possibly including schizophrenia
(Galland, 2014; Severance et al., 2015a). The link between the
gastrointestinal system and the brain is bidirectional and it is
performed through several pathways. As the brain might affect
functioning of the gut, modify microbial habitat and hence
influence the microbiota composition (Bruce-Keller et al., 2018),
at the same time, any disturbance of the microbial flora on
the surface of intestinal mucosa might lead to a number of
neuropsychiatric conditions, including schizophrenia (Petra
et al., 2015; Zhu et al., 2017). Based on the above observations,
the relationship between the brain and the gut has become a
target for the research on the pathogenesis and treatment of
several illnesses, including schizophrenia. Although collecting
and storing stool samples from individuals with schizophrenia
is challenging, interesting results have been found though the
study of the oropharyngeal microbiome (Castro-Nallar et al.,
2015; Bruce-Keller et al., 2018).
Alterations in the microbiota composition might contribute
to symptoms of schizophrenia through an immune response
or through the release of mediators, such as, amino acids, that
are able to cross the brain blood barrier or that are able to
interact with other substances that have free access to the brain.
For instance, it is well-known that the microbiota can influence
plasma level and metabolism of tryptophan and kynurenic
acid, which is a metabolite of tryptophan (Bruce-Keller et al.,
2018; Gao et al., 2018). This influence has been suggested as
a possible contributor to the pathogenesis of schizophrenia. Of
interest, kynurenic acid is a NMDA receptor antagonist which
has been involved in the pathogenesis of schizophrenia, thus
confirming the possibility of the gut to influence the brain
(Erhardt et al., 2003; Balu, 2016). Also, microbiota can change
host physiology through the production of metabolites such
as, 5-hydroxytryptophan and γ-aminobutyric acid (GABA). For
instance, Bifidobacteria and Lactobacilli can generate of GABA,
the Bacillus family can generate dopamine and noradrenaline,
and Escherichia can generate noradrenalin and 5-HT. In
addition, germs like Clostridium sporogenes decarboxylate
tryptophan to tryptamine, preventing the absorption of this
essential amino acid (Wall et al., 2014; O’Mahony et al., 2015).
Converging lines of evidence indicate a link between
schizophrenia and immune activation (Dickerson et al., 2017;
van Kesteren et al., 2017), a hypothesis that dates back to the
1950s (Severance et al., 2012). Alterations of the immune system
have been described in individuals with schizophrenia, including
T-cell activation, increased plasma cytokines, chemokines, and
increased acute phase reactants (Kronfol and Remick, 2000;
Bruce-Keller et al., 2018). Of interest, antipsychotic medications
may exert anti-inflammatory effects (Maier et al., 2018) and non-
steroid anti-inflammatory agents can reduce symptom severity in
patients with an altered immune response (Zheng et al., 2017).
This paper reviews the possible roles of the microbiome
in the development and evolution of schizophrenia, with the
ultimate goal to explore the possibility of developing new
treatments, especially for those patients with treatment resistant
presentations. Although studies on the fecal microbiome in
schizophrenia and large multi-sites placebo-controlled trials of
medications able to modify gut microbiota or inflammation in
patients with schizophrenia are still lacking, this line of research
is exciting and may hold promise.
METHODS
Searches
Cochrane library and PubMed were searched from the year 2000
to 2018 for publications about microbiome, immune-mediated
pathology, schizophrenia and neurodevelopmental disorders.
The following search string was used: (microbiome or immune
mediated) AND (schizophrenia OR neurodevelopmental
disorder). Associated publications were hand-searched from
the list of references of the identified papers. We included
“neurodevelopmental disorder” in our preliminary search
string despite the recent challenges to the neurodevelopmental
hypothesis of schizophrenia, given that neurodevelopmental
abnormalities may nonetheless contribute to- or share
pathophysiological mechanism with- schizophrenia (Owen
et al., 2011). Registries of clinical trials in controlled trials.com
and clinical trial.gov were also scrutinized.
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Study Selection
We used the Preferred Reporting Items for Systematic Reviews
and Meta-Analyses (PRISMA) course of action (Figure 1). We
deliberately chose a broad search string, given that the research
on the relationship between schizophrenia and microbiome is
still in its infancy and that we wanted to search as many
papers as possible. However, the main criteria to select the
articles for this review were the following: the study pertained to
microbiome; a schizophrenia subgroup (or sample) was part of
the study; the study outcomes for the schizophrenia subgroup (or
sample) were presented. Hence, the majority of selected papers
resulted from studies pertaining to the relationship between
microbiome, schizophrenia and the inflammatory-immunity
response system. Although the papers pertaining to review
studies, animal research, non-original studies such as, letters to
the editor, book reviews and editorials, were excluded from the
in-depth analysis, they were still considered for our preliminary
studies and discussion, and quoted as necessary. As a second step,
we conducted a narrative review about the use of probiotics and
prebiotics in schizophrenia.
Quality Assessment
First-grade studies included research on schizophrenic’s
microbiota. The second grade included studies of gastrointestinal
inflammation, infection and antimicrobial drugs in
schizophrenia that could be related to microbiome.
RESULTS
This section reports the most relevant studies pertaining to: (1)
the relationship between microbiome and schizophrenia; (2) the
relationship between schizophrenia and immune inflammatory
response; and (3) studies about probiotic and prebiotics, with
special reference to schizophrenia.
Relationship Between Microbiome and
Schizophrenia
Castro-Nallar and colleagues compared the oropharyngeal
microbiome of schizophrenic patients and healthy subjects
and found that certain types of bacteria were significantly
predominant in patients suffering of this mental condition.
In addition, they observed differences in the amount and
distribution of species, as well as different metabolic pathways.
In schizophrenic patients lactic acid bacteria and metabolite
transport system, respectively, were predominant (Castro-Nallar
et al., 2015). Yuan et al. (2018) evaluated the alterations
in microbiota in 41 drug naïve, first episode patients with
schizophrenia, after 24-weeks of treatment with risperidone.
Compared to healthy controls, schizophrenic patients had
significantly lower number of fecal Bifidobacterium, Escherichia
coli and Lactobacillus. Conversely, they had significantly higher
number of fecal Clostridium coccoides. After 24-weeks of
treatment with risperidone, a significant increase in the numbers
of fecal Bifidobacterium and E. coli was observed. Also, the
patients showed a significant decrease in the number of fecal
Clostridium coccoides and Lactobacillus. The authors concluded
that drug naïve, first episode patients with schizophrenia show
abnormalities in microbiota composition and observed that
risperidone treatment caused significant changes in fecal bacteria.
Also, they hypothesized that those changes were associated with
the metabolic changes induced by risperidone.
Schwarz et al. (2018) evaluated the differences in fecal
microbiota between 28 individuals diagnosed with first-episode
psychosis (half of whom received a diagnosis of schizophrenia by
the study 1-year follow up assessment) and 16 matched health
controls. They found that psychotic patients had higher number
of Lactobacillus bacteria. Of interest, the subgroup of patients
that showed the strongest differences in microbiota coincided
with the subjects who had a poorer response after up to 12
months of treatment.
Shen et al. (2018) evaluated the difference in gut microbiota
between 64 patients with schizophrenia and 53 healthy controls
and found a higher number of Proteobacteria, Succinivibrio,
Megasphaera, Collinsella, Clostridium, Klebsiella and
Methanbrevibacter and a lower number of Blautia, Coprococcus,
Roseburia in patients with schizophrenia compared to healthy
controls. Interestingly, the authors observed that 12 microbiota
could be used as diagnostic factors to distinguish the patients
with schizophrenia from the control cohort. Yolken et al.
(2015) investigated the relationship between schizophrenia
and bacteriophage genomes. They enrolled 41 persons with
schizophrenia and 33 healthy controls. They came to conclusion
that Lactobacillus phage phiadh was significantly more prevalent
in the oropharynx of patients with schizophrenia. The presence
of this microorganism also correlated with immunological
disorders and valproate administration in the study group.
Severance et al. (2013) measured serological surrogate
markers of bacterial translocation [soluble CD14 (sCD14) and
lipopolysaccharide binding protein (LBP)] in two cohorts. The
first one included 141 patients suffering from schizophrenia, 75
with bipolar disorder and 78 controls. In the other cohort there
were 78 with antipsychotic naïve first-episode schizophrenia and
38 with medicated first-episode schizophrenia. They found that
soluble CD14 was more prevalent in patients with schizophrenia
and both sCD14 and LBP correlated with CRP in that group.
Critchley and Harrison (2013) evaluated the impact of visceral
homeostasis on both physiological and mental capacities of the
brain and added to the studies showing that microbiota might
affect gut-brain axis at any age, leading to neurodevelopmental
or neurodegenerative conditions (Dinan and Cryan, 2017).
Relationship Between Schizophrenia and
Immune Inflammatory Response
Several studies have pointed to an association between
schizophrenia the immune-inflammatory response system
(IRS), For instance, it has been observed that people living with
schizophrenia had more prevalent inflammatory cytokine L1
receptor antagonists (Severance et al., 2012). Also, Chengappa
et al. (1995) showed that Caucasian patients suffering from
schizophrenia with HLA B8/DR3 had impaired proliferative
lymphocyte response. Ganguli et al. (1994) discovered elevated
IL-6 levels in patients with schizophrenia. Maes et al. (1997a,b)
wrote about immunological response in schizophrenia. Arolt
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FIGURE 1 | Prisma Flow Diagram.
et al. (1997) and Rothermundt et al. (1998) published similar
findings about the correlation of schizophrenia with abnormal
immunological response.
In a study involving 17 individuals with treatment-resistant
schizophrenia (TRS) 14 patients with schizophrenia showing
response to antipsychotic treatment and seven normal
controls, IL-6 was significantly higher in individuals with
schizophrenia than in healthy volunteers (HV), IL-1RA was
significantly higher in the TRS individuals than in HV, whereas
schizophrenic patients who were not treatment resistant showed
intermediate values. The authors concluded that schizophrenia
in general, and TRS in particular, are characterized by cell-
mediated immunity activation, primarily in the monocytic arm
(Maes et al., 2000).
Lin et al. (1998) examined serum Clara Cell Protein
(CC16), an endogenous protein with anti-inflammatory and
immunosuppressive properties, interleukin-6 (IL-6), IL-6
receptor (IL-6R), and IL-1R antagonist (IL-1RA) in subjects
with schizophrenia and normal controls. IL-6 and IL-6R were
significantly higher in patients with schizophrenia than in
normal controls and IL-6 was significantly higher in TRS
than in normal controls, whereas patients with non-resistant
schizophrenia TRS had intermediate values. Serum CC16 was
significantly higher in normal volunteers and schizophrenic
patients without a positive family history than in schizophrenic
patients with a family history for psychoses. A significant inverse
relationship was found between CC16 and IL-6 and IL-6R in
patients with schizophrenia, but not in normal volunteers, once
again pointing to the role of inflammation in schizophrenia,
as indicated by higher IL-6 and IL-6R serum level, which may
be linked to lower serum CC16. Müller et al. (1993) studied
55 patients with schizophrenia and observed a relationship
between cellular immune parameters and the course of the
psychopathological symptoms. It remains to be established
what the cause is for IRS activation. IRS activation could be
due to autoimmune responses (DeLisi et al., 1985; Margutti
et al., 2006) or a microbial (i.e., viral) infection or reactivation
(DeLisi and Crow, 1986). Kelly et al. (2017) suggested a
strong role of the immune system in the development of
schizophrenia; at the gene level, there is evidence about B-
lymphocyte lineages that are included in the acquired immunity
and major histocompatibility complex being related to this
condition. Findings of schizophrenic patients with elevated
levels of peripheral cytokines further confirm the possibility of
a primary role of inflammatory processes. Benros et al. (2011)
investigated if autoimmune diseases combined with exposures
to severe infections may increase the risk of schizophrenia. They
analyzed data from nationwide population-based registers in
Denmark for the period from 1977 to 2006 and linked persons
with autoimmune diseases and infections with individuals with
diagnosis of a schizophrenia spectrum disorder in the Danish
Psychiatric Central. They concluded that autoimmune disease
might increase the risk of schizophrenia by 29%, and 60% in case
of infection.
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Dickerson et al. (2014) recently reviewed the literature
concerning the immunity system, schizophrenia and bipolar
disease and focused on two studies reporting differences in
the oro-pharyngeal microbiota between schizophrenia cases
and controls. The authors also pointed to studies showing
higher rates of GI inflammation in patients with schizophrenia
or bipolar disorder and on investigations focused on the
relationship between psychiatric disorders and increased use of
antibiotics, possibly mediated by antibiotic induced changes in
microbiome.
Borovcˇanin et al. (2012) analyzed levels of serum type-1
cytokines, type-2 cytokines, type-17 cytokines and regulatory
cytokines in 88 drug-naïve patients with first episode psychosis,
45 patients with schizophrenia in relapse and in the control
group of 36 healthy persons. Patients with schizophrenia
had elevated levels of IL-4 and increased production of
TGF-β, which suggested the link between this psychiatric
condition and chronic inflammatory processes. It is noteworthy
that autoimmune conditions such as, celiac disease, i.e., a
condition resulting from the interaction between certain dietary
components and altered structure of the gastrointestinal tract,
may be linked to schizophrenia. This link was first observed
in epidemiological studies, and followed by research about
common HLA predisposition (Severance et al., 2016). Efforts
have been made to identify the role of the certain foods and
inflammatory processes in bowels, and thus severity of symptoms
of schizophrenia (Kraft and Westman, 2009).
Studies About Probiotic and Prebiotics,
With Special Reference to Schizophrenia
In light of recent findings about the link between gut microbiota
and schizophrenia, and the role of environmental factors in
the development of this illness, there might be a possibility
of using probiotics (containing species just as Lactobacillus
and Bifidobacteria) in treatment of inflammatory processes
within the gastrointestinal system, with positive effects of the
symptoms of schizophrenia. Such treatment with “psychobiotics”
could become a breakthrough in the management of mental
illnesses (Saulnier et al., 2013; Sarkar et al., 2016; Deans, 2017).
Severance and associates explored the possible relationship
between food antigen-associated immune activation in patients
with schizophrenia and gastrointestinal inflammation. They
enrolled 193 subjects with non-recent and 67 with recent onset
of schizophrenia, while there were 207 persons in the control
group. They revealed food antigen antibodies and gastrointestinal
inflammation in both schizophrenia groups (Severance et al.,
2012).
In a study published in 2015, the same authors explored
the link between dietary agents (wheat gluten and bovine milk
casein) and immune response in blood and CSF samples in 105
patients with first episode of schizophrenia and 61 persons in the
control group. In the experimental group IgG as a response to
dietary proteins were significantly higher in both serum and CSF
(Severance et al., 2015b).
Preliminary yet interesting information is emerging from
clinical trials with probiotics in the treatment of schizophrenia
(Bruce-Keller et al., 2018). Microbiome transplants from
donor mice fed with high-fat diet showed that high fat-
shaped microbiota disrupted cognitive, exploratory, and
stereotypical/impulsive behaviors (Bruce-Keller et al., 2015).
Other studies involving animal models demonstrated that
probiotics may improve cognition, mood, anxiety, while
improving neural activity and signaling (Sudo et al., 2004;
Desbonnet et al., 2010; Bravo et al., 2011; Smith et al., 2014;
Bruce-Keller et al., 2018). Also, mice studies have shown
the ability of probiotics to promote hypothalamic synaptic
plasticity and prevent decreases in hippocampal neurogenesis
induced by stress (Ait-Belgnaoui et al., 2014). Dietary trans
and saturated fats, may increase intestinal inflammation
(Deopurkar et al., 2010; Okada et al., 2013), which results in a
decrease of commensal Bacteroidetes and increase of pathogenic
Enterobacteriaceae and Proteobacteria (Lupp et al., 2007; Stecher
et al., 2007; Pédron and Sansonetti, 2008).
Karakuła-Juchnowicz et al. (2016) reviewed the role of the
food antigens in schizophrenia, the use of diet modification,
as well as antibiotics and probiotics as the possible treatment
solutions. Probiotics are microorganisms, usually Lactobacilli
and/or Bifidobacteria (Messaoudi, 2011; Tillisch et al., 2013;
Steenbergen, 2015; Sarkar et al., 2016). Prebiotics are non-
digestible carbohydrates that increase beneficial microbiota.
Prebiotics may improve emotional affect and modulate stress
responses (Schmidt et al., 2015). Randomized trials have shown
efficacy of probiotics on mood (Messaoudi, 2011; Steenbergen,
2015) as well as the ability to reduce responses to stress
(Kato-Kataoka, 2016). However, other studies have produced
controversial results and therefore more trials are needed to
completely demonstrate efficacy, to identify the specific strains
that are most beneficial, as well as the correct dose and treatment
duration (Doron and Snydman, 2015; Bruce-Keller et al., 2018).
Similarly, large, controlled and well-powered studies about the
efficacy of prebiotics are warranted (Bruce-Keller et al., 2018).
Tomasik et al. studied probiotic in schizophrenia and
found their significant impact in reducing von Willebrand
factor and increasing brain-derived neurotrophic factor (BDNF),
monocyte chemotactic protein-1 (MCP-1), T-cell-specific protein
RANTES, and macrophage inflammatory protein-1 beta (MIP-
1) beta. Also, they found that that probiotic were related to
regulation of intestinal immune and epithelial cells and suggested
that supplementation of probiotics may improve control of
gastrointestinal leakage in patients with schizophrenia (Tomasik
et al., 2015).
Dickerson et al. (2014) performed a randomized, double-
blind, placebo-controlled study and enrolled 65 patients with
schizophrenia who were first treated with double blind probiotic
or placebo for 14 weeks. Although no significant differences
between probiotics and placebo groups were found in terms of
changing schizophrenia symptoms severity, probiotics reduced
the likelihood to develop severe bowel difficulty over the course
of the trial.
Severance et al. (2017) conducted a randomized, placebo-
controlled, longitudinal pilot study and explored the use
of probiotics in treatment of both yeast gut infection and
psychiatric symptoms 56 patients with schizophrenia. Probiotics
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were associated with a decrease of Candida albicans antibody
levels as well as a decrease in gastrointestinal symptoms
in male subjects and a trends for improvement in positive
schizophrenia symptoms in males who received probiotics and
were seronegative for C. albicans.
DISCUSSION
We reviewed the relationship between microbiome and
schizophrenia as a means to speculate on the possibility that
microbiome alterations play a role in schizophrenia in general,
and in treatment resistant schizophrenia in particular. This
field of investigation is in its initial phase but the potential
role of the trillions of viruses, bacteria, and fungi that inhabit
most of our body, from the gastrointestinal tract to the
upper and lower airways, oral cavity, skin, urogenital tract,
and even tissues once thought to be sterile, such as, blood
or the eyes, is likely and worth being further explored. For
instance, Castro-Nallar, Shen and Yolken’s studies showed clear
differences in the amount and/or distribution of germs species,
as well as different metabolic pathways. However, only few
studies have explored the relationship between microbiota and
schizophrenia and—to our knowledge—no study has evaluated
the relationship between microbiota and treatment resistance
in schizophrenia. However, a hint came from Schwarz and
colleagues’ study. In fact, these authors correlated the numbers
of Lactobacilli with severity along different symptom domains
and observed that patients with the strongest microbiota
differences were also those who showed poorer response
to treatment.
We believe that the scarce data that is already available may
be helpful to formulate new hypotheses and to stimulate further
research toward a better understanding of the contribution
of microbiome and immune-mediated abnormalities to
schizophrenia and treatment resistant schizophrenia.
Although the study of microbiomes is still in its infancy
in psychiatry, other medical disciplines have already evolved
to a better understanding of its role and potential therapeutic
implications. For instance, the role of microbiome alterations
in a potentially lethal intestinal infection caused by Clostridium
difficilis has been clearly established. In fact, it is now clear
that Clostridium difficilis spreads and becomes dangerous only
when antibiotics destroy the gut’s ordinary bacterial residents
that otherwise prevent it from overgrowing. Interestingly, when
specific antibiotics against Clostridium difficilis fail, a fecal
transplant from a healthy gut, able to provide bacteria able to
suppress Clostridium difficilis may be highly effective (Brandt,
2012; Burke and Lamont, 2013; Gens et al., 2013). However,
the efficacy of fecal transplantation for psychiatric disorders in
general, and schizophrenia in particular, is yet to be appropriately
tested, despite encouraging preliminary data. For instance, an
open-label trial (Kang et al., 2017) demonstrated that children
with autism treated with fecal transplantation showed improved
behavior.
Clearly, more studies on the role of the microbiome,
probiotics, prebiotics and fecal transplantation in schizophrenia
in general, and its resistant forms in particular, are in order.
CONCLUSIONS
We are still far from considering the possibility of microbiome
targeted treatments in patients with mental illness in general,
and with schizophrenia in particular. Nonetheless, TRS remains
a challenge for researchers and practitioners and the possibility
of a role of the microbiome and of immune-mediated pathology
should be better explored, not only in animal models but also
in clinical trials of agents that are able to alter gut microbiota
and possibly influence the mechanisms of gastrointestinal
inflammation. In fact, given that alterations in the immune
system (e.g., interleukins mediated inflammatory processes
and in T-cell functions), have been considered among the
neurobiological correlates of treatment resistant schizophrenia
(Altamura et al., 2005), the possibility of agents that are
able to modulate such processes should be better explored.
More studies on the relationship between schizophrenia and
immune system alterations, as well as on the gut microbiome
and on the possibility that agents such as, probiotics may
contribute to the treatment of inflammatory processes within
the gastrointestinal system, and exert positive effects on the
symptoms of schizophrenia that are otherwise resistant to the
classic medications, are warranted.
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